title: [Use of an anti-arrhythmia drug mexicord in the treatment of ventricular extrasystole].
abstract: The antiarrhythmic agent mexicord (Polfa, Poland) versus ethmozine underwent a clinical trial. Meticord was found to have a marked antiarrhythmic effect and be useful in the long-term management of patients with ventricular tachyarrhythmias.
authors.forename: R K
authors.initials: RK
authors.lastname: Urumbaev
authors.forename: I P
authors.initials: IP
authors.lastname: Suprunova
authors.forename: D Sh
authors.initials: DSh
authors.lastname: Imanakunova
authors.forename: G R
authors.initials: GR
authors.lastname: Rakhimova
mesh_terms: D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage*; D008875:Middle Aged; D016293:Moricizine / Q000008:administration & dosage*; D011044:Poland; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D016293:Moricizine